This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458507088105v1 14/6/759    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sternberg, Z Articles by Munschauer, F Search for Related Content PubMed PubMed Citation Articles by Sternberg, Z Articles by Munschauer, F Social Bookmarking                         What's this?

Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity

¹ Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA
² Vascular Disease Center, University of Ferrara, Ferrara, Italy
³ Department of Molecular & Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
⁴ Biopolymer Facility & Mass Spectrometry, Roswell Park Cancer Institute, Buffalo, NY, USA
⁵ Department of Social & Preventive Medicine, University of Buffalo, Buffalo, NY, USA

^* To whom correspondence should be addressed.

	Abstract

Objectives

To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).

Method

37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).

Results

Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).

Conclusion

The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

Key Words: soluble receptor, inflammatory markers, cytokines, biomarker, advanced glycation

First published on May 27, 2008, doi:10.1177/1352458507088105

Multiple Sclerosis 2008;14:759.

A more recent version of this article appeared on July 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Ramasamy, S. F. Yan, and A. M. Schmidt RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts J. Leukoc. Biol., September 1, 2009; 86(3): 505 - 512. [Abstract] [Full Text] [PDF]

				S. J. Caillier, F. Briggs, B. A. C. Cree, S. E. Baranzini, M. Fernandez-Vina, P. P. Ramsay, O. Khan, W. Royal III, S. L. Hauser, L. F. Barcellos, et al. Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis J. Immunol., October 15, 2008; 181(8): 5473 - 5480. [Abstract] [Full Text] [PDF]